Hybridan Small Cap Feast: 02/07/2024
* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour
Dish of the day
Admissions:
Delistings:
What’s baking in the oven? **
Potential**** Initial Public Offerings:
ITF announced:
19 June 2024: IntelliAM, an artificial intelligence company focused on the consumer goods industry, is preparing to list on the Aquis Exchange on 3 July. The Company is acquiring 53 Degrees North Engineering Limited, to become the Company’s Consultancy division, which provides a range of asset care consulting and management strategies for manufacturers, particularly in the fast-moving consumer goods (FMCG) sector. The Consultancy division has established relationships with some of the largest food and beverage companies in the world, with 5 out of the top 10 being existing customers. IntelliAM is a revenue generating and profitable company. The Company is looking to raise £5m to fund the Company’s expansion. The Freefloat will be 16.5% following Admission and Completion of the acquisition of 53 North.
24th June 2024: Rosebank Industries: The Company aims to repeat the successful 'Buy, Improve, Sell' business model which the Rosebank Co-Founders implemented during their time at Melrose. Rosebank proposes to acquire quality industrial or manufacturing businesses whose performance may be improved. The Company’s first day of trading on AIM is expected to be 11th July 2024. The primary offer expected size is approximately £50m.
Media speculation:
Reverse Takeovers:
Change of Market:
Dual Listing:
Banquet Buffet***
68.5p £75.9m (SPA.L)
The Location Master Data Management (LMDM) software and solutions, has secured several new contracts in the US, that demonstrate material progress on the Group's US expansion plans. The US is a key part of the Group's overall growth strategy. 1Spatial now has contracts or framework agreements with 21 US States, up from 18 US States at the year end. The US business has considerable expansion potential with an ambition to generate on average $1m Annual Recurring Revenue (ARR) from each State per annum.
18.5p £80.7m (BVC.L)
The provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has signed a strategic partnership and cooperation agreement with a global technology, engineering and defence group (the Partner) to deliver the Group's advanced cybersecurity solution to commercial markets. The Partner generated revenue of over $10bn in 2023 and serves customers in more than 100 countries. Over the next two years, the Group will receive a minimum of $2.1m from the Partner for the product customisation phase and the provision of an initial quantity of units, which will be delivered in three phases over the two years. The Group is due to commence delivering the units to the Partner by the end of the first half of 2025.
24.5p £26.5m (CKT.L)
The automated monitoring platform for operational leaders, announces a significant expansion with an existing UK customer. Checkit has signed a new contract with an integrated energy company to provide real time operations management capabilities to 150 additional franchisees in the UK. The sites will be installed in tranches over the duration of the 32-month contract. The full value of the contract is worth c.£250k annually and is additional to the contract announced on 15 April 2024 for 50 franchisees.
302.5p £48.7m (CML.L)
The Company that develops mixed-signal, RF and microwave semiconductors for global communications markets, announces its results for the year ended 31 March 2024. Revenue increased 11% to £22.89m (2023: £20.64m). Profit from operations was £1.94m (FY23: £2.93m pre-exceptional profit from the sale of excess land). The cash balance at end of period was £18.21m (2023: £22.26m) following a share buyback of £1.75m, dividend payments of £1.74m and CapEx investments of £1.54m. The Company notes that external factors such as current market conditions and the normalisation of elevated customer inventory levels, make it difficult to achieve short-term profits and growth objectives.
50p £11.0m (DSW.L)
The mid-market, challenger professional services licence network and owner of the Dow Schofield Watts brand, announces its year results for the year ended 31 March 2024. Revenue decreased to £2.3m (2023: £3.0m), Adjusted EBITDA decreased to £0.6m (2023: £1.5m) and the cash balance at the end of the period was £2.6m (2023: £4.6m) following acquisitions of Bridgewood and STS Europe, and investment in new start up licensees. The Group enters the new financial year with 25 licensees and a record number of Fee Earners and Partners, creating a strong platform for when market conditions return. The new financial year has started in line with expectations.
27.75p £188.8m (HVO.L)
The specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has been engaged for a Phase 2b field study assessing an influenza candidate. This contract is with a US company (the client) and will commence later this year with hVIVO enrolling up to 1,000 healthy volunteers as part of a multi-centre study with hVIVO being selected as the sole UK clinical site. Furthermore, the Company will be holding a Capital Markets Event at its new state-of-the-art facility in Canary Wharf on Wednesday 17 July 2024 at 10.00 am - 12.30 pm (BST). The Company also expects to announce a trading update for the six months ended 30 June 2024 on the same day.
313.25p £219.6m (KITW.L)
The delivered wholesale business announces its unaudited interim results for the six months ended 30 April 2024. Revenue increased 8% to £297.0m (H1 2023: £275.0m), Adjusted EBITDA was £15.9m (H1 2023: £16.0m) and cash and cash equivalents increased to £5.02m (H1 2023: £3.29m). Despite the slight shortfall in operating profit in H1 FY24 and the continued wet weather in May and early June, the Company expects to be in line with market expectations for the full year ending 31 October 2024.
* 0.075p £1.3m (MDZ.L)
The creative audio-visual solutions provider announces that CEO Geoff Robertson will provide a live presentation relating to the Company’s Half Year Results via Investor Meet Company on 9 July 2024 at 11:00 BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the shareholder’s Investor Meet Company dashboard up until 8 July 2024 at 09:00 BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet MediaZest via: https://www.investormeetcompany.com/ mediazest-plc/register-investor.
127.5p £58.9m (SHOE.L)
The specialist multi-channel footwear retailer announces that, further to its AGM Statement released on 12 March 2024 it has continued to experience cost pressures associated with container prices due to a reduction in the supply of shipping vessels and the continuation of a reroute away from the Suez Canal. As a result, container prices have risen significantly over the last six months. Alongside an increase in shipping costs, the Company has experienced weaker than expected Spring Summer sales from April to June, due to unseasonal weather conditions. As a result, the Company now expects adjusted profit before tax for the financial year ending 2 October 2024 to be not less than £10.0m.
172p £200.5m (SUP.L)
The manufacturer, supplier and brand owner of fast-moving consumer products announces its audited results for the year ended 31 March 2024. Revenue increased 42% to £221.2m (2023: £155.6m), profit before tax increased 109% to £30.1m (2023: £14.4m) and cash and cash equivalents increased to £11.63m (2023: £7.54m). Supreme forecasts FY25 to be another profitable and highly cash-generative year for the Group. Having made a positive start in Q1, the Group is trading comfortably in line with current market expectations.
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.